Literature DB >> 23518811

Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population.

John D Betteridge1, Steven P Armbruster, Corinne Maydonovitch, Ganesh R Veerappan.   

Abstract

BACKGROUND: There is limited data examining the prevalence of inflammatory bowel disease (IBD) in a diverse North American population.
METHODS: Using International Classification of Diseases, Ninth Revision codes, patients with Crohn's disease (CD) and ulcerative colitis (UC) seen within the military health care system (Tricare) from October 1, 2008 to September 30, 2009 were identified. This database comprised all active duty military, retirees, and dependents. The overall prevalence of IBD, UC, and CD was calculated, and the prevalence by age, gender, race, and geographic location.
RESULTS: A total of 35,404 cases of IBD were identified in 10.2 million military health care beneficiaries establishing a prevalence of total IBD, UC, and CD of 348, 202, and 146 per 100,000, respectively. IBD was more prevalent in females compared with males (417 versus 284 per 100,000; relative risk, 1.53; 95% confidence interval, 1.50-1.57). There was an increased prevalence of IBD with each decade of life. IBD was more common in Caucasians (324 per 100,000) compared with blacks, Asians, Hispanics, and American Indians (239, 162, 147, and 224 per 100,000, respectively; relative risk, 1.60; 95% confidence interval, 1.53-1.67). There was no difference in prevalence when comparing Northern versus Southern states (339 versus 333 per 100,000, respectively, P = 0.114).
CONCLUSIONS: This large population study establishes a prevalence of IBD, UC, and CD (348, 202, and 146 per 100,000, respectively) in the military health care population. The prevalence of IBD, UC, and CD was higher in females and with increasing age, whereas IBD was most common in whites compared with other ethnicities in our patient population.

Entities:  

Mesh:

Year:  2013        PMID: 23518811     DOI: 10.1097/MIB.0b013e318281334d

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  35 in total

1.  Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.

Authors:  Chengrui Huang; Talin Haritunians; David T Okou; Dermot P B McGovern; Steven R Brant; Subra Kugathasan; David J Cutler; Michael E Zwick; Kent D Taylor; Lisa W Datta; Joseph C Maranville; Zhenqiu Liu; Shannon Ellis; Pankaj Chopra; Jonathan S Alexander; Robert N Baldassano; Raymond K Cross; Themistocles Dassopoulos; Tanvi A Dhere; Richard H Duerr; John S Hanson; Jason K Hou; Sunny Z Hussain; Kim L Isaacs; Kelly E Kachelries; Howard Kader; Michael D Kappelman; Jeffrey Katz; Richard Kellermayer; Barbara S Kirschner; John F Kuemmerle; Archana Kumar; John H Kwon; Mark Lazarev; Peter Mannon; Dedrick E Moulton; Bankole O Osuntokun; Ashish Patel; John D Rioux; Jerome I Rotter; Shehzad Saeed; Ellen J Scherl; Mark S Silverberg; Ann Silverman; Stephan R Targan; John F Valentine; Ming-Hsi Wang; Claire L Simpson; S Louis Bridges; Robert P Kimberly; Stephen S Rich; Judy H Cho; Anna Di Rienzo; Linda W H Kao
Journal:  Gastroenterology       Date:  2015-08-14       Impact factor: 22.682

2.  Sex- and corticotropin-releasing factor receptor 2- dependent actions of urocortin 1 during inflammation.

Authors:  Burcu Hasdemir; Pallavi Mhaske; Sreenivasan Paruthiyil; Elizabeth A Garnett; Melvin B Heyman; Mehrdad Matloubian; Aditi Bhargava
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-04-06       Impact factor: 3.619

Review 3.  The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease.

Authors:  Jessica F Brinkworth; Luis B Barreiro
Journal:  Curr Opin Immunol       Date:  2014-10-22       Impact factor: 7.486

Review 4.  Hispanic Americans and Non-Hispanic White Americans Have a Similar Inflammatory Bowel Disease Phenotype: A Systematic Review with Meta-Analysis.

Authors:  Danny J Avalos; Antonio Mendoza-Ladd; Marc J Zuckerman; Mohammad Bashashati; Andres Alvarado; Alok Dwivedi; Oriana M Damas
Journal:  Dig Dis Sci       Date:  2018-03-29       Impact factor: 3.199

Review 5.  Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease.

Authors:  Wendy A Goodman; Ian P Erkkila; Theresa T Pizarro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09-08       Impact factor: 46.802

6.  Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Joel Pekow; Ashwin Ananthakrishnan; Adjoa Anyane-Yeboa; Christopher Martin; Joseph Galanko; Hans H Herfarth; Michael D Kappelman; Robert S Sandler
Journal:  Inflamm Bowel Dis       Date:  2018-11-29       Impact factor: 5.325

7.  Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies.

Authors:  Hai Yun Shi; Alexander N Levy; Hirsh D Trivedi; Francis K L Chan; Siew C Ng; Ashwin N Ananthakrishnan
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-08       Impact factor: 11.382

8.  Impact of sex on 30-day complications and long-term functional outcomes following ileal pouch-anal anastomosis for chronic ulcerative colitis.

Authors:  Nicholas P McKenna; Eric J Dozois; John H Pemberton; Amy L Lightner
Journal:  Int J Colorectal Dis       Date:  2018-03-16       Impact factor: 2.571

9.  Race/Ethnicity-Specific Disparities in the Severity of Disease at Presentation in Adults with Ulcerative Colitis: A Cross-Sectional Study.

Authors:  Garland Castaneda; Benny Liu; Sharon Torres; Taft Bhuket; Robert J Wong
Journal:  Dig Dis Sci       Date:  2017-08-30       Impact factor: 3.199

10.  Male Gender Is Associated with a High Risk for Chronic Antibiotic-Refractory Pouchitis and Ileal Pouch Anastomotic Sinus.

Authors:  Xian-Rui Wu; Jean Ashburn; Feza H Remzi; Yi Li; Hagar Fass; Bo Shen
Journal:  J Gastrointest Surg       Date:  2015-10-07       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.